To which drug class does ipratropium bromide belong?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ipratropium Bromide Drug Class

Ipratropium bromide is an anticholinergic (antimuscarinic) bronchodilator, specifically classified as a short-acting muscarinic antagonist (SAMA).

Mechanism of Action

Ipratropium bromide functions as a parasympatholytic agent that antagonizes acetylcholine at muscarinic receptors on bronchial smooth muscle 1. By blocking these receptors, it prevents increases in cyclic guanosine monophosphate (cyclic GMP) that would otherwise cause bronchoconstriction 1. This anticholinergic mechanism inhibits vagally-mediated reflexes in the airways 2, 1.

Classification Within Bronchodilator Categories

The drug belongs to the broader category of inhaled muscarinic antagonists (anticholinergics), which are recognized as important pharmacologic bronchodilators for COPD management 3. More specifically:

  • Short-acting formulation: Unlike tiotropium (a long-acting muscarinic antagonist or LAMA), ipratropium requires dosing every 6 hours due to its shorter duration of action 2, 4
  • Quaternary ammonium compound: Chemically related to atropine but exists in an ionized state, making it relatively insoluble in non-polar media and unable to cross the blood-brain barrier 1

Clinical Context

Guidelines consistently identify ipratropium as a short-acting muscarinic antagonist (SAMA) when discussing treatment algorithms for COPD 2, 3. It provides bronchodilation with onset within 15-30 minutes, peak effect at 1-2 hours, and duration of 4-5 hours in most patients 1. The drug is frequently preferred over beta-agonists in some contexts due to minimal cardiac stimulatory effects 5.

In summary: Ipratropium bromide = Anticholinergic = Antimuscarinic = Short-Acting Muscarinic Antagonist (SAMA)

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.